Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 2/20 | 0.57 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 5/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | AOC2 | O75106 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL321866 | 0.98 | TAAR1 (0.58) | TAAR1LTA4HPLA2G2AESR1CYP19A1 | |
| SCHEMBL9633819 | 0.94 | LTA4H (0.68) | TAAR1LTA4HPLA2G2AESR1CYP19A1 | |
| SCHEMBL1010758 | 0.88 | MAOB (0.52) | TAAR1ESR1CYP19A1ESR2MAOB | |
| SCHEMBL6714503 | 0.87 | TAAR1 (0.75) | TAAR1LTA4HPLA2G2AESR1CYP19A1 | |
| Hydrochloric Acid SCHEMBL4377848 | 0.86 | MAOB (0.55) | MAOBCYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL9114592 | 0.85 | CYP1A2 (0.63) | LTA4HMAOBCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7972309 | 0.85 | MEN1 (0.54) | MAOB | |
| SCHEMBL15923247 | 0.85 | MEN1 (0.54) | MAOB | |
| SCHEMBL1620167 | 0.83 | APP (0.52) | LTA4HMAOBCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10338308 | 0.82 | MEN1 (0.60) | LTA4HCYP1A2CYP2D6CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345785-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO RAD LABORATORIES INC (US) | 2025-11-13 | — | — | US | claimed |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | BIO-RAD LABORATORIES, INC. (US) | 2024-02-13 | — | — | US | claimed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | ALI MOHAMMED A | 2010-03-04 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| CN-101203244-A | Compositions of rennin inhibitor and insulin secernent or insulin sensitizer | NOVARTIS AG (CH) | 2008-06-18 | — | — | CN | claimed |
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | claimed |
| CN-101163504-A | Combination therapy | XENON PHARMACEUTICALS INC (CA) | 2008-04-16 | — | — | CN | claimed |
| EP-1907004-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| WO-2007005763-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2007-01-11 | — | — | WO | claimed |
| EP-1268412-B1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2006-11-22 | — | — | EP | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | claimed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | claimed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK CANADA INC. (CA) | 2004-02-12 | — | — | US | claimed |
| JP-2003528076-A | — | — | 2003-09-24 | — | — | JP | claimed |
| EP-1268412-A1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 2003-01-02 | — | — | EP | claimed |
| WO-2001070677-A1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 2001-09-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | TAAR1 2591/4885LTA4H 1917/4885PLA2G2A 456/4885 |
| US-20250345785-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | ABCG2, SLC7A1, MSR1 | TAAR1 2870/4885LTA4H 1364/4885PLA2G2A 1166/4885 |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | ABCG2, SLC7A1, MSR1 | TAAR1 2870/4885LTA4H 1364/4885PLA2G2A 1166/4885 |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | REN, IAPP, ACE | TAAR1 2579/4885LTA4H 2445/4885PLA2G2A 4474/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | TAAR1 2558/4885LTA4H 1997/4885PLA2G2A 1799/4885 |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | BACE1, BACE2, PSEN2 | TAAR1 4024/4885LTA4H 2302/4885PLA2G2A 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.